Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,824.50GBp
22 Sep 2017
Change (% chg)

22.00 (+0.58%)
Prev Close
3,802.50
Open
3,826.00
Day's High
3,860.00
Day's Low
3,793.00
Volume
1,793,329
Avg. Vol
2,962,282
52-wk High
5,331.00
52-wk Low
3,603.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.53
Market Cap(Mil.): £34,960.99
Shares Outstanding(Mil.): 908.29
Dividend: 3.85
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

Sep 20 2017

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO, Sept 20 Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

Sep 20 2017

BRIEF-Shire and Shionogi announce positive topline results for Intuniv ​

* ‍SHIRE AND SHIONOGI ANNOUNCE POSITIVE TOPLINE RESULTS FOR INTUNIV EVALUATED IN PHASE 3 CLINICAL TRIAL IN ADULTS WITH ADHD​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Sep 20 2017

BRIEF-Shire receives FDA fast track designation for SHP607

* SHIRE RECEIVES FDA FAST TRACK DESIGNATION FOR SHP607 FOR THE PREVENTION OF CHRONIC LUNG DISEASE IN EXTREMELY PREMATURE INFANTS

Sep 12 2017

BRIEF-Shire announces collaboration with Microhealth to address needs of hemophilia A and B patients with inhibitors

* Shire announces collaboration with Microhealth to address unique needs of hemophilia A and B patients with inhibitors Source text for Eikon: Further company coverage:

Aug 25 2017

Shire's CFO resigns to join plant technology start-up

LONDON Pharmaceutical company Shire said its chief financial officer Jeff Poulton will stand down at the end of the year to join Indigo Ag, a Boston-based start-up that seeks to improve agricultural productivity.

Aug 21 2017

Shire's CFO resigns to join plant technology start-up

LONDON, Aug 21 Pharmaceutical company Shire said its chief financial officer Jeff Poulton will stand down at the end of the year to join Indigo Ag, a Boston-based start-up that seeks to improve agricultural productivity.

Aug 21 2017

BRIEF-Shire says CFO Jeff Poulton to leave at end of year

* Jeff Poulton, chief financial officer, will be leaving Shire at end of year to serve as CFO at Indigo AG Source text for Eikon: Further company coverage:

Aug 21 2017

BRIEF-Jana Partners dissolves sole share stake in Snap Inc, Shire Plc

* Jana Partners Llc ups sole share stake in Hewlett Packard Enterprise Co to 10.2 million shares from 4.4 million shares

Aug 14 2017

Shire may spin off hyperactivity drugs, raises forecasts

LONDON Shire, the London-listed pharmaceutical firm built up by acquisitions, said it might spin off its hyperactivity drugs business into a separate company and focus solely on rare disease treatments.

Aug 03 2017

Earnings vs. Estimates